{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T17:18:22Z","timestamp":1787937502104,"version":"build-2784847793"},"reference-count":51,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Patients with chronic kidney disease (CKD) exhibit a higher cardiovascular risk compared to the general population, due to CKD itself and its associated metabolic disorders, such as dyslipidemia. While statin-based management is the current gold standard therapy for dyslipidemia in mild to moderate CKD patients, it has a limited effect on lipoproteins, other than low density lipoproteins such as Lp(a). This limitation should be taken into consideration in cardiovascular risk stratification. Furthermore, statin therapy has not shown any beneficial effects in dialysis patients without prior cardiovascular disease, leading to uncertainty regarding the optimal dyslipidemia management in kidney failure (KF) patients. In this context, high serum Lp(a) levels (&amp;gt;105\u2005nmol\/L) should be acknowledged as a significant cardiovascular risk factor due to their pro-atherosclerotic and pro-calcific effects. However, selective Lp(a)-lowering therapies are still lacking in current clinical practice, although novel therapies are emerging in promising Phase III randomized trials. This narrative review summarizes the role of Lp(a) in CKD and discusses current state of the art and future therapeutic strategies.<\/jats:p>","DOI":"10.1093\/joneph\/aajag084","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T12:43:28Z","timestamp":1774529008000},"page":"884-891","source":"Crossref","is-referenced-by-count":0,"title":["Lp(a) in chronic kidney disease: state of the art and management perspectives"],"prefix":"10.1093","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8883-4776","authenticated-orcid":false,"given":"Leonardo","family":"Spatola","sequence":"first","affiliation":[{"name":"Division of Nephrology and Dialysis, Ospedale Sant\u2019 Antonio Abate, AspTrapani , via Cosenza, Erice, TP ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8784-1552","authenticated-orcid":false,"given":"Rosario","family":"Maccarrone","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Dialysis, Ospedale Cannizzaro , Via Messina, Catania, CT ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Zeiler","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Dialysis, Ospedale \u201cCarlo Urbani\u201d , Jesi, AN ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Granata","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Dialysis, Ospedale Cannizzaro , Via Messina, Catania, CT ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"key":"2026082812320949300_aajag084-B1","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1093\/eurheartj\/ehaf167","article-title":"Cardiovascular disease in chronic kidney disease","volume":"46","author":"Marx-Sch\u00fctt","year":"2025","journal-title":"Eur Heart J"},{"key":"2026082812320949300_aajag084-B2","doi-asserted-by":"publisher","first-page":"835","DOI":"10.5551\/jat.RV22006","article-title":"Nakano T role of Chronic Kidney Disease (CKD)-Mineral and Bone Disorder (MBD) in the pathogenesis of cardiovascular disease in CKD","volume":"30","author":"Yamada","year":"2023","journal-title":"J Atheroscler Thromb."},{"key":"2026082812320949300_aajag084-B3","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41569-023-00947-2","article-title":"Lipoprotein(a), platelet function and cardiovas- cular disease","volume":"21","author":"Bhatia","year":"2024","journal-title":"Nat Rev Cardiol"},{"key":"2026082812320949300_aajag084-B4","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1038\/sj.ki.5002240","article-title":"Evidence mounts for a role of the kidney in lipoprotein(a) catabolism","volume":"71","author":"Albers","year":"2007","journal-title":"Kidney Int"},{"key":"2026082812320949300_aajag084-B5","doi-asserted-by":"publisher","first-page":"76","DOI":"10.5935\/abc.20140101","article-title":"Lipoprotein(a): structure, pathophysiology and clinical implications","volume":"103","author":"Maranh\u00e3o","year":"2014","journal-title":"Arq Bras Cardiol"},{"key":"2026082812320949300_aajag084-B6","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/0005-2760(79)90131-0","article-title":"Lipoprotein(a) is not a metabolic product of other lipoproteins containing apolipoprotein B","volume":"575","author":"Krempler","year":"1979","journal-title":"Biochim Biophys Acta."},{"key":"2026082812320949300_aajag084-B7","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.atherosclerosis.2022.04.009","article-title":"Beyond fibrinolysis: the confounding role of Lp(a) in thrombosis","volume":"349","author":"Boffa","year":"2022","journal-title":"Atherosclerosis"},{"key":"2026082812320949300_aajag084-B8","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1161\/ATV.0000000000000147","article-title":"Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association","volume":"42","author":"Reyes-Soffer","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"2026082812320949300_aajag084-B9","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/S2213-8587(17)30088-8","article-title":"Apolipoprotein(a) isoform size, lipoprotein(a) concentration, and coronary artery disease: a Mendelian randomisation analysis","volume":"5","author":"Saleheen","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026082812320949300_aajag084-B10","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1161\/ATVBAHA.114.303315","article-title":"Factor XII regulates the pathological process of thrombus formation on ruptured plaques","volume":"34","author":"Kuijpers","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"2026082812320949300_aajag084-B11","doi-asserted-by":"publisher","first-page":"e1082","DOI":"10.1161\/CIR.0000000000000625","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"2026082812320949300_aajag084-B12","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur\u00a0Heart J."},{"key":"2026082812320949300_aajag084-B13","doi-asserted-by":"publisher","first-page":"e312","DOI":"10.1016\/j.jacl.2024.03.001","article-title":"A focused update to the 2019 NLA scientific statement on use of Lipoprotein(a) in clinical practice","volume":"18","author":"Koschinsky","year":"2024","journal-title":"J Clin Lipidol"},{"key":"2026082812320949300_aajag084-B14","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.atherosclerosis.2025.120479","article-title":"2025 focused update of the 2019 ESC\/EAS Guidelines for the management of dyslipidaemias","volume":"409","author":"Mach","year":"2025","journal-title":"Atherosclerosis"},{"key":"2026082812320949300_aajag084-B15","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1126\/science.2530631","article-title":"The mysteries of Lipoprotein(a)","volume":"246","author":"Utermann","year":"1989","journal-title":"Science"},{"key":"2026082812320949300_aajag084-B16","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/MOL.0000000000000753","article-title":"The impact of race and ethnicity on Lipoprotein(a) levels and cardiovascular risk","volume":"32","author":"Reyes-Soffer","year":"2021","journal-title":"Curr Opin Lipidol."},{"key":"2026082812320949300_aajag084-B17","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated Lipoprotein(a) and increased risk of myocardial infarction","volume":"301","author":"Kamstrup","year":"2009","journal-title":"JAMA"},{"key":"2026082812320949300_aajag084-B18","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1161\/ATVBAHA.118.310865","article-title":"Genetic factors explain a major fraction of the 50% lower Lipoprotein[a] concentrations in Finns","volume":"38","author":"Erhart","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026082812320949300_aajag084-B19","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/j.1365-2796.2012.02592.x","article-title":"Lipoprotein(a)\u2014resurrected by genetics.","volume":"273","author":"Kronenberg","year":"2013","journal-title":"J Intern Med"},{"key":"2026082812320949300_aajag084-B20","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/joim.20027","article-title":"Lipoprotein(a) concentrations and cardiovascular disease in patients with chronic kidney disease: results from the German Chronic Kidney Disease study","volume":"296","author":"Gruber","year":"2024","journal-title":"J Intern Med"},{"key":"2026082812320949300_aajag084-B21","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/S0272-6386(99)70147-2","article-title":"Apolipoprotein(a) phenotypes and Lipoprotein(a) concentrations in patients with renal failure","volume":"33","author":"Milionis","year":"1999","journal-title":"Am J Kidney Dis."},{"key":"2026082812320949300_aajag084-B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/kisup.2012.73","article-title":"Kidney disease: improving global outcomes (KDIGO) CKD Work Group: KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"Levin","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"2026082812320949300_aajag084-B23","doi-asserted-by":"publisher","first-page":"647","DOI":"10.3109\/0886022X.2010.486097","article-title":"Lipoprotein-A and carotid intima media thickness as cardiovascular risk factors in patients of chronic kidney disease","volume":"32","author":"Aggarwal","year":"2010","journal-title":"Ren Fail."},{"key":"2026082812320949300_aajag084-B24","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1111\/dme.12862","article-title":"Lipoprotein(a) predicts a new onset of chronic kidney disease in people with type 2 diabetes mellitus","volume":"33","author":"Yun","year":"2016","journal-title":"Diabet Med."},{"key":"2026082812320949300_aajag084-B25","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1016\/j.jacc.2016.10.033","article-title":"Phenotypic characterization of genetically lowered human Lipoprotein(a) levels","volume":"68","author":"Emdin","year":"2016","journal-title":"J Am Coll Cardiol."},{"key":"2026082812320949300_aajag084-B26","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.2215\/CJN.09320913","article-title":"Relation of serum lipids and lipoproteins with progression of CKD: the CRIC study","volume":"9","author":"Rahman","year":"2014","journal-title":"Clin J Am Soc Nephrol."},{"key":"2026082812320949300_aajag084-B27","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/s10157-013-0875-8","article-title":"Causes and consequences of Lipoprotein(a) abnormalities in kidney disease","volume":"18","author":"Kronenberg","year":"2014","journal-title":"Clin Exp Nephrol."},{"key":"2026082812320949300_aajag084-B28","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1159\/000188426","article-title":"Lipoprotein(a) levels and fibrinolytic activity in patients with nephrotic syndrome","volume":"69","author":"Hong","year":"1995","journal-title":"Nephron"},{"key":"2026082812320949300_aajag084-B29","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1161\/01.ATV.14.9.1399","article-title":"Apolipoprotein(a) phenotype-associated decrease in Lipoprotein(a) plasma concentrations after renal transplantation","volume":"14","author":"Kronenberg","year":"1994","journal-title":"Arterioscler Thromb."},{"key":"2026082812320949300_aajag084-B30","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1194\/jlr.R051904","article-title":"Lipoprotein (a): impact by ethnicity and environmental and medical conditions","volume":"57","author":"Enkhmaa","year":"2016","journal-title":"J Lipid Res."},{"key":"2026082812320949300_aajag084-B31","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1053\/j.ajkd.2016.01.016","article-title":"Effect of statins on kidney disease outcomes: a systematic review and meta-analysis","volume":"67","author":"Su","year":"2016","journal-title":"Am J Kidney Dis."},{"key":"2026082812320949300_aajag084-B32","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study of heart and renal pro\u00adtection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"2026082812320949300_aajag084-B33","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"German diabetes and dialysis study investigators: atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"N Engl J Med"},{"key":"2026082812320949300_aajag084-B34","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","article-title":"Rosuvastatin and cardiovascular events in patients undergoing hemodialysis","volume":"360","author":"Fellstr\u00f6m","year":"2009","journal-title":"N Engl J Med"},{"key":"2026082812320949300_aajag084-B35","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1194\/jlr.R053066","article-title":"Current therapies for lowering Lipoprotein (a)","volume":"57","author":"van Capelleveen","year":"2016","journal-title":"J Lipid Res."},{"key":"2026082812320949300_aajag084-B36","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1093\/eurjpc\/zwab171","article-title":"Statin therapy and Lipoprotein(a) levels: a systematic review and meta-analysis","volume":"29","author":"de Boer","year":"2022","journal-title":"Eur J Prev Cardiol."},{"key":"2026082812320949300_aajag084-B37","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extendedrelease niacin with laropiprant in high-risk patients","volume":"371","author":"Landray","year":"2014","journal-title":"N Engl J Med."},{"key":"2026082812320949300_aajag084-B38","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Boden","year":"2011","journal-title":"N Engl J Med."},{"key":"2026082812320949300_aajag084-B39","doi-asserted-by":"publisher","first-page":"1625417","DOI":"10.3389\/fmed.2025.1625417","article-title":"Targeting cardiovascular and metabolic risk modification in end stage renal disease (ESRD): a randomized controlled clinical trial on niacin's effects on Lipoprotein(a) and biochemical markers in hemodialysis patients","volume":"12","author":"Galal","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"2026082812320949300_aajag084-B40","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med."},{"key":"2026082812320949300_aajag084-B41","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1161\/CIRCULATIONAHA.113.001969","article-title":"AMG145, a monoclonal antibodyagainst proprotein convertase subtilisin kexin type 9, significantly reduces Lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial","volume":"128","author":"Desai","year":"2013","journal-title":"Circulation"},{"key":"2026082812320949300_aajag084-B42","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1194\/jlr.R056549","article-title":"Lipoprotein apheresis to treat elevated lipoprotein(a)","volume":"57","author":"Waldmann","year":"2016","journal-title":"J Lipid Res."},{"key":"2026082812320949300_aajag084-B43","doi-asserted-by":"publisher","DOI":"10.1055\/a-2768-2477","article-title":"Clinical response to elevated Lipoprotein(a): practical approach for risk management in the absence of targeted therapies","author":"Sanchis-Gomar","year":"2025","journal-title":"Semin Thromb Hemost"},{"key":"2026082812320949300_aajag084-B44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ahj.2025.03.019","article-title":"Design and rationale of Lp(a)HORIZON trial: assessing the effect of lipoprotein(a) lowering with pelacarsen on major cardiovascular events in patients with CVD and elevated Lp(a)","volume":"287","author":"Cho","year":"2025","journal-title":"Am Heart J"},{"key":"2026082812320949300_aajag084-B45","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ahj.2022.05.004","article-title":"Study design and rationale for the olpasiran trials of cardiovascular events and LipoproteiN(a) reduction-DOSE finding study (OCEAN(a)-DOSE)","volume":"251","author":"O'Donoghue","year":"2022","journal-title":"Am Heart J"},{"key":"2026082812320949300_aajag084-B46","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa2415818","article-title":"Lepodisiran\u2014A long-duration small interfering RNA targeting Lipoprotein(a)","volume":"392","author":"Nissen","year":"2025","journal-title":"N Engl J Med."},{"key":"2026082812320949300_aajag084-B47","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1001\/jama.2024.21957","article-title":"Zerlasiran-A small-interfering RNA targeting Lipoprotein(a): a phase 2 randomized clinical trial","volume":"332","author":"Nissen","year":"2024","journal-title":"JAMA"},{"key":"2026082812320949300_aajag084-B48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jacadv.2025.102068","article-title":"Primary prevention aspirin, Lipoprotein(a), and cardiorenal outcomes in chronic kidney disease chronic renal insufficiency cohort","volume":"4","author":"Razavi","year":"2025","journal-title":"JACC Adv"},{"key":"2026082812320949300_aajag084-B49","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.jacc.2022.07.027","article-title":"Aspirin for primary prevention of cardiovascular events in relation to Lipoprotein(a) genotypes","volume":"80","author":"Lacaze","year":"2022","journal-title":"J Am Coll Cardiol."},{"key":"2026082812320949300_aajag084-B50","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s11427-022-2171-2","article-title":"RNA therapeutics: updates and future potential","volume":"66","author":"Zhang","year":"2023","journal-title":"Sci China Life Sci."},{"key":"2026082812320949300_aajag084-B51","doi-asserted-by":"publisher","first-page":"114432","DOI":"10.1016\/j.bcp.2021.114432","article-title":"The growth of siRNA-based therapeutics: updated clinical studies","volume":"189","author":"Zhang","year":"2021","journal-title":"Biochem Pharmacol."}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/joneph\/article-pdf\/39\/5\/884\/70243840\/aajag084.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/joneph\/article-pdf\/39\/5\/884\/70243840\/aajag084.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T16:32:12Z","timestamp":1787934732000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/39\/5\/884\/8743937"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":51,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,8,28]]},"published-print":{"date-parts":[[2026,8,28]]}},"URL":"https:\/\/doi.org\/10.1093\/joneph\/aajag084","relation":{},"ISSN":["1121-8428","1724-6059"],"issn-type":[{"value":"1121-8428","type":"print"},{"value":"1724-6059","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,6]]}}}